These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26498259)

  • 1. Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations.
    Napolitano C
    Heart Rhythm; 2016 Feb; 13(2):614-5. PubMed ID: 26498259
    [No Abstract]   [Full Text] [Related]  

  • 2. Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
    Wangüemert-Pérez F; Ruiz-Hernández PM; Campuzano O; Caballero-Dorta E; Bosch C; Brugada J; Brugada R
    Minerva Cardioangiol; 2014 Aug; 62(4):363-6. PubMed ID: 25012103
    [No Abstract]   [Full Text] [Related]  

  • 3. Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Napolitano C; Venetucci LA; Priori SG
    Trends Cardiovasc Med; 2012 Feb; 22(2):35-9. PubMed ID: 22867967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.
    Biernacka EK; Hoffman P
    Europace; 2011 Jan; 13(1):129-30. PubMed ID: 20798117
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
    Kohli U; Aziz Z; Beaser AD; Nayak HM
    Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Vaksmann G; Klug D
    Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Jacquemart C; Ould Abderrahmane F; Massin MM
    J Electrocardiol; 2012; 45(6):736-8. PubMed ID: 22672791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
    J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trans-2,3-enoyl-CoA reductase-like-related catecholaminergic polymorphic ventricular tachycardia with regular ventricular tachycardia and response to flecainide.
    Ebrahim MA; Alkhabbaz AA; Albash B; AlSayegh AH; Webster G
    J Cardiovasc Electrophysiol; 2023 Sep; 34(9):1996-2001. PubMed ID: 37473425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxysmal bidirectional ventricular tachycardia with tachycardiomyopathy in a pregnant woman.
    Walker NL; Cobbe SM; McGavigan AD
    Acta Cardiol; 2009 Jun; 64(3):419-22. PubMed ID: 19593958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
    Hong RA; Rivera KK; Jittirat A; Choi JJ
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
    Padfield GJ; AlAhmari L; Lieve KV; AlAhmari T; Roston TM; Wilde AA; Krahn AD; Sanatani S
    Heart Rhythm; 2016 Feb; 13(2):609-13. PubMed ID: 26416620
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents].
    Le Davay M; Victor J; Dupuis JM; Merheb M; Tran P; Tadeï A
    Ann Cardiol Angeiol (Paris); 1994 May; 43(5):253-5. PubMed ID: 8074416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
    Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
    Watanabe H; Chopra N; Laver D; Hwang HS; Davies SS; Roach DE; Duff HJ; Roden DM; Wilde AA; Knollmann BC
    Nat Med; 2009 Apr; 15(4):380-3. PubMed ID: 19330009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports.
    van der Werf C; Wilde AA
    Europace; 2011 Jan; 13(1):11-3. PubMed ID: 20851823
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; Steele DS; Knollmann BC
    Circ Res; 2011 Sep; 109(6):712-3. PubMed ID: 21885838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.